Get started
Author

Nora Schenk

Observed name: Nora L. Schenk
OpenAlex ID: A5113557843
Effective inhibition of aromatase inhibitor‐associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole
2008 · Nigel J. Bundred, Ian D. Campbell, et al. · Cancer · 218
Integrated Analysis of Zoledronic Acid for Prevention of Aromatase Inhibitor–Associated Bone Loss in Postmenopausal Women with Early Breast Cancer Receiving Adjuvant Letrozole
2008 · Adam Brufsky, Nigel Bundred, et al. · The Oncologist · 175
Immediate Administration of Zoledronic Acid Reduces Aromatase Inhibitor–Associated Bone Loss in Postmenopausal Women With Early Breast Cancer: 12-Month Analysis of the E-ZO-FAST Trial
2011 · Antonio Llombart, Antonio Frassoldati, et al. · Clinical Breast Cancer · 131
On Two Localized Particle Filter Methods for Lorenz 1963 and 1996 Models
2022 · Nora Schenk, Roland Potthast, et al. · Frontiers in Applied Mathematics and Statistics · 5
PDF
Encuesta Nacional de Demografía y Salud Reproductiva 1995-1996
1997 · María M. Mealián, Amelia Mazó, et al. · 2
An open-label, multicenter, expanded access study assessing the safety and efficacy of oral ruxolitinib administered to patients with primary myelofibrosis (PMF), post-polycythemia myelofibrosis (PPV MF) or post-essential thrombocythemia myelofibrosis (PET-MF).
2012 · Philipp D. le Coutre, Heinz Gisslinger, et al. · Journal of Clinical Oncology · 1
Works count: 6
Citation count: 532
H-index: 4
I10-index: 3
Year
Topic
Type